The estimated Net Worth of Lloyd Mitchell Segal is at least $3.15 million dollars as of 28 March 2024. Mr Segal owns over 5,141 units of Repare Therapeutics stock worth over $302,238 and over the last 4 years he sold RPTX stock worth over $1,967,880. In addition, he makes $878,368 as Pres et CEO & Director at Repare Therapeutics.
Mr has made over 9 trades of the Repare Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 5,141 units of RPTX stock worth $23,751 on 28 March 2024.
The largest trade he's ever made was selling 41,000 units of Repare Therapeutics stock on 3 June 2021 worth over $1,275,510. On average, Mr trades about 5,507 units every 98 days since 2020. As of 28 March 2024 he still owns at least 107,558 units of Repare Therapeutics stock.
You can see the complete history of Mr Segal stock trades at the bottom of the page.
Lloyd Mitchell Segal is the Pres, CEO & Director at Repare Therapeutics.
As the Pres et CEO & Director of Repare Therapeutics, the total compensation of Mr Segal at Repare Therapeutics is $878,368. There are no executives at Repare Therapeutics getting paid more.
Mr Segal is 57, he's been the Pres et CEO & Director of Repare Therapeutics since . There are 1 older and 2 younger executives at Repare Therapeutics. The oldest executive at Repare Therapeutics Inc. is Dr. Maria Koehler M.D., Ph.D., 64, who is the Exec. VP & Chief Medical Officer.
Lloyd's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., , ST-LAURENT, A8, H4S 1Z9.
Over the last 4 years, insiders at Repare Therapeutics have traded over $111,956,457 worth of Repare Therapeutics stock and bought 8,747,790 units worth $117,182,784 . The most active insiders traders include Partners L P/Ilbiotechnolog..., David P Bonita et Group, Llc Green Jeremy Red.... On average, Repare Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $446,135. The most recent stock trade was executed by Lloyd Mitchell Segal on 28 March 2024, trading 5,141 units of RPTX stock currently worth $23,751.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
Repare Therapeutics executives and other stock owners filed with the SEC include: